Financial Performance - Consolidated system-wide sales grew by 6.9% year-over-year, reaching $12,282 million in Q3 2025, compared to $11,433 million in Q3 2024[2][3] - Comparable sales accelerated to 4.0%, with notable performances of 6.4% at Burger King International, 4.2% at Tim Hortons Canada, and 3.2% at Burger King US[2][3] - Adjusted Operating Income (AOI) increased to $702 million in Q3 2025, reflecting an organic AOI growth of 8.8%[3][12] - Net income from continuing operations rose to $440 million, with diluted earnings per share from continuing operations at $0.96[3][12] - Total revenues for Q3 2025 reached $2,449 million, a 6.9% increase from $2,291 million in Q3 2024[36] - Net income attributable to common shareholders for Q3 2025 was $315 million, compared to $252 million in Q3 2024, reflecting a 25% increase[36] - Basic net income per share from continuing operations increased to $0.97 in Q3 2025, up from $0.79 in Q3 2024[36] - Adjusted EBITDA for the three months ended September 30, 2025, was $794 million, up 6.0% from $748 million in 2024[58] - Adjusted diluted earnings per share for Q3 2025 increased to $1.03 from $0.93 in Q3 2024, marking a 10.8% rise[67] Sales Growth - System-wide sales growth for Tim Hortons was 4.8% in Q3 2025, with total revenues of $1,125 million[11][12] - Burger King's system-wide sales grew by 2.3% in Q3 2025, totaling $2,956 million[14] - System-wide Sales for Burger King reached $1,519 million in Q3 2025, reflecting a 0.7% growth compared to Q3 2024[19] - Comparable Sales in the US decreased by 2.0% in Q3 2025, while international comparable sales increased by 6.4%[21] - The FHS segment reported a System-wide Sales growth of 10.7% in Q3 2025, with Total Revenues increasing to $60 million from $53 million[20] - The INTL segment achieved System-wide Sales of $5,447 million in Q3 2025, a significant increase from $4,780 million in Q3 2024[21] Investments and Acquisitions - The acquisition of Carrols Restaurant Group and Popeyes China was completed in 2024, establishing a new segment, Restaurant Holdings[4][5] - Burger King is investing up to $700 million in its "Reclaim the Flame" plan through 2028, focusing on advertising, digital investments, and restaurant enhancements[17] - The company expects to incur additional costs related to acquisitions in 2025, indicating ongoing market expansion efforts[68] Financial Position - The company reported a net leverage ratio of 4.4x, down from 4.8x in the previous year[3] - Total assets as of September 30, 2025, were $25,669 million, an increase from $24,632 million as of December 31, 2024[38] - Cash and cash equivalents decreased to $1,206 million as of September 30, 2025, down from $1,334 million at the end of 2024[38] - Long-term debt, net of current portion, was $13,415 million as of September 30, 2025, slightly down from $13,455 million at the end of 2024[38] - The company’s total liabilities increased to $20,504 million as of September 30, 2025, compared to $19,789 million at the end of 2024[38] Cash Flow and Capital Management - Net cash provided by operating activities from continuing operations increased to $1,159 million, up 13.4% from $1,022 million in the previous year[40] - Net cash used for investing activities from continuing operations decreased significantly to $213 million from $616 million in 2024, indicating improved capital management[40] - Free Cash Flow (FCF) is calculated as net cash provided by operating activities minus payments for property and equipment, serving as a liquidity measure[55] - Free cash flow for the nine months ended September 30, 2025, was $996 million, compared to $898 million in 2024, representing an increase of 11.0%[65] Future Outlook - The company is on track for at least 8% organic Adjusted Operating Income growth in 2025[2] - For 2025, the company expects consolidated capital expenditures to be around $400 million[27] - The company anticipates achieving over 5% Net Restaurant Growth towards the end of its long-term performance period from 2024 to 2028[28] - The company plans to enhance operations and drive long-term sustainable growth through various strategies, including refranchising efforts and new partnerships in international markets[34] Tax and Regulatory Considerations - The effective tax rate increased due to the impact of OECD Pillar II guidance, affecting future tax planning strategies[68]

Financial Performance - Third quarter 2025 net sales were $4.2 billion, consistent with the prior year, with organic sales growth of 2.5% driven by 2.4% volume growth [4]. - Year-to-date sales totaled $12.4 billion, a decrease of 2.6%, primarily due to a 3.0% negative impact from divestitures and foreign currency translation [12]. - Net sales for Q3 2025 were $4,150 million, a slight increase of 0.1% compared to $4,144 million in Q3 2024 [40]. - For the nine months ended September 30, 2025, net sales were $12,367 million, a decrease of 2.6% from $12,701 million in the same period of 2024 [42]. - Total net sales for the nine months ended September 30, 2025, were $12,367 million, down 2.6% from $12,701 million in 2024 [48]. Profitability - Gross margin for the quarter was 36.0%, with an adjusted gross margin of 36.8%, down 170 basis points year-over-year due to pricing pressures and cost inflation [5]. - Diluted earnings per share (EPS) attributable to Kimberly-Clark were $1.34, down from $2.69 in the prior year, while adjusted EPS were $1.82, broadly in line with the previous year [11]. - Operating profit decreased by 39.5% to $621 million in Q3 2025 from $1,026 million in Q3 2024 [40]. - Net income attributable to Kimberly-Clark Corporation fell by 50.8% to $446 million in Q3 2025, down from $907 million in Q3 2024 [40]. - Operating profit for the nine months ended September 30, 2025, was $1,844 million, down 19.1% from $2,280 million in 2024 [42]. - Net income for the nine months ended September 30, 2025, was $1,539 million, a decrease of 27.6% compared to $2,126 million in 2024 [46]. Cash Flow and Capital Expenditures - Adjusted free cash flow is expected to be approximately $2 billion in 2025 [30]. - Cash provided by operations for the nine months ended September 30, 2025, was $1,805 million, down 25.4% from $2,417 million in 2024 [46]. - Capital spending for the nine months ended September 30, 2025, was $741 million, an increase of 44.7% compared to $512 million in 2024 [46]. - Cash and cash equivalents at the end of the period were $634 million, down 43% from $1,111 million at the end of the same period in 2024 [46]. Debt and Assets - Total debt as of September 30, 2025, was $7.3 billion, down from $7.4 billion as of December 31, 2024 [25]. - Total assets as of September 30, 2025, were $16,888 million, an increase from $16,546 million at the end of 2024 [44]. - Current liabilities increased to $7,077 million as of September 30, 2025, compared to $7,004 million at the end of 2024 [44]. Taxation - The Effective Tax Rate as reported for Q3 2025 was 45.4%, significantly higher than 19.4% in Q3 2024 [62]. - The Adjusted Effective Tax Rate for the nine months ended September 30, 2025, was 22.6%, compared to 21.7% in the same period of 2024 [62]. Transformation Initiative - The company initiated a 2024 Transformation Initiative aimed at improving growth trajectory and profitability [56]. - The company is focusing on its 2024 Transformation Initiative to enhance operational efficiency and drive future growth [61]. - The 2024 Transformation Initiative contributed $62 million to income from continuing operations in Q3 2025, compared to $(12) million in Q3 2024 [62].

Financial Performance - Consolidated net sales for Q3 2025 were $1.63 billion, a 50.6% increase year-over-year from $1.08 billion in Q3 2024[5] - Non-GAAP adjusted EBITDA for Q3 2025 was $402.5 million, representing a 97.1% increase from $204.2 million in Q3 2024[14] - GAAP income from continuing operations was $106.9 million, compared to a loss of $96.7 million in the prior year[13] - RemainCo net sales reached $516.3 million, a 49.4% increase from $345.5 million in Q3 2024[5] - Net sales for Q3 2025 reached $1,629.7 million, a significant increase from $1,082.2 million in Q3 2024, representing a growth of approximately 50.7%[33] - Gross profit for Q3 2025 was $667.8 million, compared to $435.1 million in Q3 2024, indicating a gross margin improvement from 40.3% to 41.0%[33] - Operating income for the nine months ended September 30, 2025, was $670.9 million, a substantial increase from $138.9 million in the same period of 2024[33] - The company reported a net income attributable to common stockholders of $91.1 million in Q3 2025, compared to a net loss of $49.4 million in Q3 2024[33] - Basic earnings per share for Q3 2025 was $0.41, recovering from a loss of $0.23 in Q3 2024[33] - Net income for Q3 2025 was $108.4 million, a significant improvement from a net loss of $33.0 million in Q3 2024[37] Cash Flow and Liquidity - Cash flow generated by operations was $151.4 million, with free cash flow of $135.0 million after capital expenditures[25] - Total liquidity at the end of Q3 2025 was approximately $1.28 billion, with $705 million in cash and cash equivalents[25] - Cash and cash equivalents increased to $705.3 million as of September 30, 2025, up from $564.9 million at the end of 2024[35] - The company reported a total of $151.4 million in net cash generated by operating activities for Q3 2025, compared to $122.2 million in Q3 2024[37] Debt and Assets - Total assets decreased to $7,939.1 million as of September 30, 2025, down from $8,747.5 million at the end of 2024[35] - Long-term debt was reduced to $7,254.9 million as of September 30, 2025, compared to $9,238.4 million at the end of 2024, reflecting a decrease of approximately 21.5%[35] - The company’s long-term debt repayment for the nine months ended September 30, 2025, was $2,049.0 million, compared to $24.0 million in the same period of 2024[37] Segment Performance - ANS and RUCKUS segments achieved a combined non-GAAP adjusted EBITDA of $344 million, a 135% increase year-over-year[11] - The ANS segment saw a remarkable 77.2% increase in net sales, reaching $337.8 million in Q3 2025 compared to $190.6 million in Q3 2024[48] - The RUCKUS segment achieved net sales of $178.5 million in Q3 2025, a 15.2% increase from $154.9 million in Q3 2024[48] - The CCS segment reported net sales of $1,113.4 million for Q3 2025, reflecting a 51.1% increase from $736.7 million in Q3 2024[48] Future Outlook - The company raised its 2025 consolidated adjusted EBITDA guidance to between $1.30 billion and $1.35 billion[9] - The outlook for consolidated adjusted EBITDA in 2025 is projected to be between $1,300 million and $1,350 million[61] - RemainCo adjusted EBITDA for 2025 is expected to range from $350 million to $375 million[62] - The CCS segment is expected to close in Q1 2026, with plans for a special dividend to common shareholders post-transaction[10] Risks and Challenges - The company is currently facing risks related to the proposed acquisition by Amphenol Corporation, which may impact ongoing business operations and customer relationships[29] - Future performance may be affected by economic downturns, inflation, and the ability to implement price increases on products and services[30]

Financial Performance - PYRUKYND net revenues for Q3 2025 were $12.9 million, a 44% increase from $9.0 million in Q3 2024 and a 3% increase from $12.5 million in Q2 2025[6] - The company reported a net loss of $103.4 million for Q3 2025, compared to a net income of $947.9 million in Q3 2024, which included milestone payments and royalty sales[9] - As of September 30, 2025, Agios had $1.3 billion in cash, cash equivalents, and marketable securities, down from $1.5 billion at the end of 2024[12] Drug Development and Trials - The PDUFA goal date for PYRUKYND's supplemental New Drug Application in thalassemia is set for December 7, 2025[5] - Enrollment in the Phase 2b tebapivat trial for lower-risk MDS is fully completed, with topline results expected in early 2026[5] - The RISE UP Phase 3 trial topline results in sickle cell disease are expected by year-end 2025, potentially leading to a U.S. commercial launch in 2026[5] Patient Enrollment and Therapy - 262 unique patients completed prescription enrollment forms for PYRUKYND, representing a 6% increase over Q2 2025[6] - 149 patients are currently on therapy in the U.S., reflecting a 5% increase from Q2 2025[6] Expenses - Research and Development expenses for Q3 2025 were $86.8 million, an increase of $14.3 million compared to Q3 2024[12] - Selling, General and Administrative expenses for Q3 2025 were $41.3 million, up $2.7 million from Q3 2024, driven by preparations for the potential U.S. launch of PYRUKYND[12]

Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Commission File Number 0-19311 BIOGEN INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 33-0112644 (I.R.S. Employe ...

Financial Performance - Third quarter 2025 net sales totaled $2.0 billion, a decrease from $2.1 billion in the same quarter of the prior year, with comparable store sales increasing by 3.0%[4] - Gross profit for the third quarter 2025 was $0.9 billion, representing 43.3% of net sales, an increase from 42.3% in the prior year, driven by cost savings from footprint optimization and strategic sourcing initiatives[5] - Selling, general and administrative (SG&A) expenses were $0.9 billion, or 42.2% of net sales, slightly down from 42.3% in the prior year, with adjusted SG&A expenses at $0.8 billion, or 40.4% of net sales[6] - Operating income for the third quarter 2025 was $22 million, or 1.1% of net sales, compared to break-even operating income in the same quarter of the prior year, with adjusted operating income at $90 million, or 4.4% of net sales[7] - The diluted earnings per share for the quarter was $(0.02), an improvement from $(0.42) in the third quarter of 2024, while adjusted diluted earnings per share was $0.92 compared to $(0.05) in the prior year[12] - Free cash flow through the third quarter of 2025 was an outflow of $277 million, compared to an outflow of $49 million in the same period of the prior year, including approximately $130 million in cash charges related to restructuring[13] - Net sales for the twelve weeks ended October 4, 2025, were $2,036 million, a decrease of 5.2% compared to $2,148 million for the same period in 2024[25] - Gross profit for the forty weeks ended October 4, 2025, was $2,864 million, down 6.4% from $3,061 million in 2024[25] - Operating loss for the twelve weeks ended October 4, 2025, was $22 million, compared to an operating income of $0 million in the same period of 2024[25] - Net income from continuing operations for the forty weeks ended October 4, 2025, was $38 million, an increase from $23 million in 2024[27] - The company reported a net cash used in operating activities of continuing operations of $118 million for the forty weeks ended October 4, 2025[27] - The company’s basic earnings per share from continuing operations was $(0.02) for the twelve weeks ended October 4, 2025, compared to $(0.42) in the same period of 2024[25] - For the twelve weeks ended October 4, 2025, the company reported a net loss from continuing operations of $1 million, compared to a loss of $25 million for the same period in 2024[34] - Adjusted net income for the twelve weeks ended October 4, 2025, was $56 million, a significant improvement from a loss of $3 million in the same period last year[34] - The company's gross profit for the twelve weeks ended October 4, 2025, was $913 million, with an adjusted gross profit margin of 44.8%, compared to 42.3% in the same period of 2024[40] - Selling, general and administrative (SG&A) expenses for the twelve weeks ended October 4, 2025, were $823 million, resulting in an adjusted SG&A margin of 40.4%[41] - The company experienced a free cash flow of $(277) million for the forty weeks ended October 4, 2025, which includes approximately $130 million of cash charges related to restructuring[43] Liquidity and Debt - The company ended the quarter with over $3 billion in cash on the balance sheet, indicating a strong liquidity position[9] - Cash and cash equivalents at the end of the period were $3,174 million, significantly up from $491 million at the end of the previous year[28] - The company raised $1,950 million through the issuance of long-term debt during the forty weeks ended October 4, 2025[27] - Total debt as of October 4, 2025, was $3.411 billion, with an adjusted net debt of $2.489 billion[44] - The adjusted net debt to adjusted EBITDAR ratio was 2.6, indicating the company's leverage position[44] Future Outlook and Strategy - The company has updated its full year 2025 guidance, projecting net sales from continuing operations between $8,550 million and $8,600 million, with comparable store sales growth expected between 0.7% and 1.3%[16] - The company plans to open 30 new stores and 14 new market hubs in the upcoming period, maintaining its growth strategy[16] - The company declared a regular cash dividend of $0.25 per share, to be paid on January 23, 2026, to stockholders of record as of January 9, 2026[14] - The company incurred $33 million in restructuring and related expenses during the twelve weeks ended October 4, 2025[25] - The company recorded $37 million in gross profit adjustments for the forty weeks ended October 4, 2025, reflecting ongoing transformation efforts[42] - The company anticipates continued restructuring and transformation expenses, which are expected to impact future financial performance[46] - The company emphasizes the use of non-GAAP financial measures to provide insight into its core operating performance and future prospects[29] Store Operations - During the forty weeks ended October 4, 2025, the company opened 26 new stores while closing 517, resulting in a total of 4,297 stores[45]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________________________________ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-37454 CSW INDUSTRIALS, INC. (Exact name of registrant as specified in its charter) (State or ...

Exhibit 99.1 AMNEAL REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS ‒ Q3 2025 Net Revenue of $785 million; GAAP Net Income of $2 million; Diluted Income per Share of $0.01 ‒ ‒ Adjusted EBITDA of $160 million; Adjusted Diluted EPS of $0.17 ‒ ‒ Updated 2025 Full Year Guidance ‒ BRIDGEWATER, NJ, October 30, 2025 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced its results for the third quarter ended September 30, 2025. "Amneal delivered another strong quarter and updated o ...

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 Ralph.Giacobbe@TheCignaGroup.com MEDIA CONTACT: Justine Sessions 860-810-6523 Justine.Sessions@Evernorth.com The Cigna Group Reports Strong Third Quarter 2025 Results, Reaffirms 2025 Adjusted EPS Outlook BLOOMFIELD, CT, October 30, 2025 – Global health company The Cigna Group (NYSE: CI) today reported third quarter 2025 results that reflect strategic execution across its diverse portfolio of businesses. "Our strong quarterly ...

News Release Integra LifeSciences Reports Third Quarter 2025 Financial Results PRINCETON, N.J., October 30, 2025 - Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2025. Third Quarter 2025 Highlights Codman Specialty Surgical (~70% of Revenues) Total revenues were $292.6 million, representing reported growth of 8.1% and organic growth of 7.1% compared to the third quarter of 2024 ...